Kanye West gig in Italy cancelled over ‘public order and safety issues’ A concert by fellow US rapper Travis Scott at Hellwatt Festival has also been scrapped. Evening Standard · May 30
Jamo's Concert series gets an encore with two new ranges from the newly resurrected brand The two new Scandi ranges are available in August. What Hi-Fi? · May 6
“Well suited for everything from bluesy porch pickin’ to speakeasy swingin’”: Gretsch drops two limited edition Jim Dandy parlour and concert acoustics with solid spruce tops and off-the-charts vintage mojo They're small-bodied, budget-friendly, inspired by ye olde Rex catalogue pre-War models... Get 'em while they're hot, people MusicRadar · Jun 3, 2025
Gretsch glow-up: One of our favorite parlor guitars just got a limited-edition makeover – and at $249, it’s still irresistibly affordable The Jim Dandy has been given an ornate new finish and an updated spec sheet, making it more desirable than ever before Guitar World · May 30, 2025
Exclusive: Israeli documents show expansive government effort to shape US discourse around Gaza war As the Gaza war rages, Israeli funds target US college campuses and push to redefine antisemitism in US law The Guardian - US · Jun 24, 2024
Recap Of Monday's Biotech Catalysts - End Of the Day Summary The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand… Benzinga · Aug 1, 2022
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial. Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)… Benzinga · May 23, 2022
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted The US Patent Trial and Appeal Board (PTAB) issued a final written decision in favor of Concert Pharmaceuticals Inc (NASDAQ:CNCE) regarding the post-grant review (PGR) for the '659 method-of-use patent. The '659 patent claims methods of treating hair loss, including alopecia areata with certain doses of CTP-543, a deuterated form of ruxolitinib, JAK 1/2… Benzinga · May 13, 2022